207 related articles for article (PubMed ID: 18322986)
1. Elevation of serum lymphotactin levels in patients with systemic sclerosis.
Muroi E; Ogawa F; Shimizu K; Komura K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 May; 35(5):834-8. PubMed ID: 18322986
[TBL] [Abstract][Full Text] [Related]
2. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis.
Furuse S; Fujii H; Kaburagi Y; Fujimoto M; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2003 Jul; 30(7):1524-8. PubMed ID: 12858452
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.
Fujii H; Shimada Y; Hasegawa M; Takehara K; Sato S
J Dermatol Sci; 2004 Jun; 35(1):43-51. PubMed ID: 15194146
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
[TBL] [Abstract][Full Text] [Related]
5. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
Kodera M; Hayakawa I; Komura K; Yanaba K; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2005 Apr; 32(4):629-36. PubMed ID: 15801017
[TBL] [Abstract][Full Text] [Related]
6. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Matsushita T; Yanaba K; Kodera M; Komura K; Takehara K; Sato S
Rheumatology (Oxford); 2005 Jul; 44(7):873-8. PubMed ID: 15797972
[TBL] [Abstract][Full Text] [Related]
7. Elevated circulating CD40L concentrations in patients with systemic sclerosis.
Komura K; Sato S; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2004 Mar; 31(3):514-9. PubMed ID: 14994397
[TBL] [Abstract][Full Text] [Related]
8. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.
Tomita H; Ogawa F; Hara T; Yanaba K; Iwata Y; Muroi E; Yoshizaki A; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2010 Apr; 37(4):787-91. PubMed ID: 20156945
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis.
Ogawa F; Shimizu K; Muroi E; Hara T; Hasegawa M; Takehara K; Sato S
Rheumatology (Oxford); 2006 Jul; 45(7):815-8. PubMed ID: 16449367
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
[TBL] [Abstract][Full Text] [Related]
12. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis.
Hasegawa M; Fujimoto M; Kikuchi K; Takehara K
J Rheumatol; 1997 Feb; 24(2):328-32. PubMed ID: 9034992
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis.
Hara T; Ogawa F; Yanaba K; Iwata Y; Muroi E; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2009 Jan; 36(1):99-105. PubMed ID: 19208531
[TBL] [Abstract][Full Text] [Related]
16. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
Nishijima C; Sato S; Takehara K
J Rheumatol; 2001 Aug; 28(8):1847-51. PubMed ID: 11508588
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
[TBL] [Abstract][Full Text] [Related]
18. Increased serum interleukin 23 in patients with systemic sclerosis.
Komura K; Fujimoto M; Hasegawa M; Ogawa F; Hara T; Muroi E; Takehara K; Sato S
J Rheumatol; 2008 Jan; 35(1):120-5. PubMed ID: 18085738
[TBL] [Abstract][Full Text] [Related]
19. Increased serum pentraxin 3 in patients with systemic sclerosis.
Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF.
Matsushita T; Fujimoto M; Hasegawa M; Tanaka C; Kumada S; Ogawa F; Takehara K; Sato S
J Rheumatol; 2007 Oct; 34(10):2056-62. PubMed ID: 17896803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
